Skip to main content

Table 2 Changes from baseline to week 8 of anthropometric and metabolic parameters in cilostazol and placebo group (n=37)

From: Effect of cilostazol on arterial stiffness and vascular adhesion molecules in type 2 diabetic patients with metabolic syndrome: a randomised, double-blind, placebo-controlled, crossover trial

 

Placebo

Cilostazol

 

Baseline

Follow-up

P-value

Baseline

Follow-up

P-value

BMI (kg/m2)

26.2 ± 2.9

26.2 ± 2.9

0.29

26.2 ± 2.9

26.0 ± 2.9

0.12

Waist circumference (cm)

92.5 ± 8.0

92.1 ± 7.6

0.36

92.6 ± 8.0

91.4 ± 7.4

0.007

Systolic blood pressure (mmHg)

131.0 ± 10.8

131.1 ± 12.0

0.93

130.6 ± 11.2

129.6 ± 13.0

0.59

Diastolic blood pressure (mmHg)

79.6 ± 11.2

81.3 ± 10.3

0.35

79.4 ± 9.8

77.4 ± 9.3

0.20

Fasting glucose (mg/dL)

129.2 ± 22.2

129.6 ± 32.0

0.94

137.5 ± 41.2

140.2 ± 31.7

0.66

HbA1c (%)*

7.2 ± 1.2

7.1 ± 1.2

0.19

7.3 ± 1.2

7.2 ± 1.2

0.42

Fasting insulin (μIU/mL)*

11.0 ± 1.6

11.0 ± 1.6

0.99

11.1 ± 1.5

10.3 ± 1.5

0.21

HOMA-IR*

3.5 ± 1.6

3.6 ± 1.7

0.50

3.6 ± 1.6

3.5 ± 1.6

0.73

QUICKI

0.32 ± 0.02

0.32 ± 0.02

0.59

0.32 ± 0.02

0.32 ± 0.02

0.74

Total cholesterol (mg/dL)

156.7 ± 24.2

154.1 ± 23.6

0.49

157.9 ± 21.0

154.9 ± 23.0

0.39

Triglyceride (mg/dL)*

143.9 ± 1.7

140.7 ± 1.6

0.77

134.6 ± 1.6

121.9 ± 1.5

0.19

HDL-C (mg/dL)

43.0 ± 9.3

44.7 ± 13.1

0.37

47.1 ± 11.0

48.1 ± 10.9

0.41

LDL-C (mg/dL)

94.1 ± 21.6

90.3 ± 19.9

0.28

93.9 ± 19.9

88.9 ± 20.0

0.10

hsCRP (mg/L)*

1.09 ± 2.78

0.93 ± 3.28

0.39

0.90± 2.79

1.15 ± 2.24

0.09

Mean baPWV (cm/sec)

1597.9 ± 239.6

1606.7 ± 259.6

0.77

1621.8 ± 229.8

1592.0 ± 249.3

0.35

Adiponectin (ng/mL)*

8.44 ± 1.82

8.53 ± 1.95

0.72

9.17 ± 1.88

9.92 ± 1.93

0.07

IL-6 (pg/mL)*

4.13 ± 3.14

3.21 ± 3.34

0.02

4.33 ± 3.28

3.41 ± 2.48

0.74

TNF-α (ng/dL)*

6.66 ± 1.32

6.12 ± 1.36

0.07

6.42 ± 1.32

6.36 ± 1.37

0.87

MCP-1 (ng/dL)*

546.6 ± 1.43

577.5 ± 1.38

0.32

588.1 ± 1.57

570.4 ± 1.43

0.67

sVCAM-1 (ng/dL)

1227.6 ± 274.0

1225.1 ± 281.4

0.94

1288.7 ± 285.6

1168.2 ± 252.3

0.0003

sICAM-1 (ng/dL)*

158.4 ± 1.38

156.3 ± 1.39

0.70

155.2 ± 1.38

144.0 ± 1.35

0.10

  1. HOMA-IR homeostasis model assessment of insulin resistance, QUICKI quantitative insulin sensitivity check index, hsCRP high sensitivity C-reactive protein, baPWV brachial-ankle pulse wave velocity, IL-6 interleukin-6, TNF-α tumor necrosis factor-alpha, MCP-1 monocyte chemotactic protein-1, sVCAM-1 soluble vascular cellular adhesion molecule-1, sICAM-1 soluble intercellular adhesion molecule-1.
  2. Data are presented as the mean ± SD.
  3. *Geometric mean ± SD, statistical significance was estimated after logarithmic transformation.
  4. P-value were obtained using paired t-test based on change (follow-up–baseline) in each group.
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us